CompletedNCT00107939
Licarbazepine added to antipsychotic treatment for mania
About this title
Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
Read the official source — NCT00107939This study evaluated the safety and effectiveness of Licarbazepine for people with bipolarity.
Medication studyAges 18–70United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Licarbazepine for people with bipolarity.
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- Little Rock and 21 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 453
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00107939
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Licarbazepine 750 ¿ 2000 mg/d as Adjunctive Therapy to an Atypical Antipsychotic in the Treatment of Manic Episodes of Bipolar I Disorder Over 6 Weeks
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Little Rock · Orange · Pico Rivera
18 more locations
- San Diego
- Boca Raton
- Atlanta
- Chicago
- Joliet
- Indianapolis
- Topeka
- Kansas City
- St Louis
- Brooklyne
- Cedarhurst
- New York
- Cincinnati
- Columbus
- Providence
- Bellaire
- Bellevue
- West Allis
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Licarbazepine for people with bipolarity.
Who is behind this study?
The study sponsor is Novartis Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Licarbazepine.
Who was this study for?
Listed age limits: 18 years to 70 years.
